Representative Rick W. Allen (Republican-Georgia) recently sold shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on June 05th, the Representative disclosed that they had sold between $15,001 and $50,000 in Abbott Laboratories stock on April 16th. The trade occurred in the Representative’s “R.W. ALLEN & ASSOCIATES, INC. > RWA&A – SECURITIES” account.
Representative Rick W. Allen also recently made the following trade(s):
- Sold $15,001 – $50,000 in shares of Intuit (NASDAQ:INTU) on 4/16/2026.
- Sold $15,001 – $50,000 in shares of Procter & Gamble (NYSE:PG) on 4/16/2026.
- Sold $15,001 – $50,000 in shares of S&P Global (NYSE:SPGI) on 4/16/2026.
- Sold $50,001 – $100,000 in shares of Ameriprise Financial (NYSE:AMP) on 4/15/2026.
Abbott Laboratories Stock Down 2.3%
NYSE:ABT traded down $2.10 on Wednesday, reaching $89.15. The stock had a trading volume of 11,838,350 shares, compared to its average volume of 11,897,081. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The company has a 50-day moving average of $92.26 and a 200 day moving average of $108.64. The stock has a market cap of $155.29 billion, a P/E ratio of 24.97, a price-to-earnings-growth ratio of 1.51 and a beta of 0.63. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $139.06.
Insider Buying and Selling
In related news, Director Daniel J. Starks bought 10,000 shares of the business’s stock in a transaction on Monday, April 27th. The stock was bought at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the transaction, the director directly owned 6,751,103 shares in the company, valued at $625,489,692.95. This represents a 0.15% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Philip P. Boudreau bought 2,200 shares of the business’s stock in a transaction on Thursday, April 23rd. The stock was bought at an average price of $91.50 per share, with a total value of $201,300.00. Following the transaction, the chief financial officer owned 2,200 shares in the company, valued at approximately $201,300. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 0.46% of the stock is owned by corporate insiders.
Analysts Set New Price Targets
Several equities research analysts recently weighed in on ABT shares. BTIG Research reiterated a “buy” rating and set a $131.00 price objective on shares of Abbott Laboratories in a research note on Monday, April 27th. Piper Sandler cut their target price on shares of Abbott Laboratories from $135.00 to $115.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. Evercore cut their target price on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Wells Fargo & Company cut their target price on shares of Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. Finally, UBS Group cut their target price on shares of Abbott Laboratories from $158.00 to $135.00 and set a “buy” rating for the company in a research note on Monday, April 20th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average price target of $119.09.
View Our Latest Stock Analysis on ABT
Institutional Investors Weigh In On Abbott Laboratories
Hedge funds have recently made changes to their positions in the company. Cornerstone Financial Management LLC purchased a new stake in shares of Abbott Laboratories in the 4th quarter valued at approximately $25,000. MidAtlantic Capital Management Inc. purchased a new stake in shares of Abbott Laboratories in the 4th quarter valued at approximately $25,000. Purpose Unlimited Inc. purchased a new stake in Abbott Laboratories in the 4th quarter worth approximately $25,000. Portfolio Resources Advisor Group Inc. purchased a new stake in Abbott Laboratories in the 4th quarter worth approximately $26,000. Finally, Abound Financial LLC purchased a new stake in Abbott Laboratories in the 4th quarter worth approximately $26,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.
Key Headlines Impacting Abbott Laboratories
Here are the key news stories impacting Abbott Laboratories this week:
- Positive Sentiment: Abbott’s cancer diagnostics growth story is drawing support after its Exact Sciences acquisition expanded the company’s cancer testing portfolio, while new data and screening guidelines could boost demand going forward. Mounting Evidence Backs Abbott’s Cancer Diagnostics Growth Story
- Positive Sentiment: Abbott also secured CE Mark approval for Libre Duo and Libre Duo 10 Day, the world’s first dual glucose-ketone sensing technology for diabetes, which adds to its diabetes device growth runway. Abbott (ABT) Secures CE Mark for World’s First Dual Glucose-Ketone Sensing Technology for Diabetes
- Positive Sentiment: Several recent articles continue to describe Abbott as a blue-chip, long-term holding for investors seeking stability and dividend income, which can support sentiment around the stock. New Investors: 3 Rock-Solid Stocks to Build Your Portfolio Around
- Neutral Sentiment: Abbott Laboratories is also trending among Zacks users, suggesting elevated investor interest, but that alone does not confirm a clear operational catalyst. Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
- Neutral Sentiment: One commentary argued Abbott has improved versus five years ago but still may not be a buy at current levels, reflecting ongoing debate over valuation after the stock’s recent slump. Abbott Laboratories: A Better Than 5 Years Ago – But Still Not A Buy
About Representative Allen
Rick Allen (Republican Party) is a member of the U.S. House, representing Georgia’s 12th Congressional District. He assumed office on January 3, 2015. His current term ends on January 3, 2027.
Allen (Republican Party) ran for re-election to the U.S. House to represent Georgia’s 12th Congressional District. He won in the general election on November 5, 2024.
Allen was born in Augusta, Georgia, in 1951. He attended Auburn University in Alabama, graduating in 1973 with a B.S. in building construction.
After earning his degree, Allen worked as an estimator, project administrator and assistant to the president with a construction firm in Augusta. In 1976, he founded his own construction business, R. W. Allen & Associates, Inc. The company operates in six states across the country. In 2008, Allen was presented with the Augusta Metro Chamber of Commerce’s Small Business Person of the Year award.
About Abbott Laboratories
Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.
In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.
Featured Articles
- Five stocks we like better than Abbott Laboratories
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
- Intel Is the Market’s Most Mispriced AI Hedge
- The Biggest Opportunity From SpaceX’s IPO May Surprise You
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
